How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases
Cardiovascular disease (CVD) causes millions of deaths worldwide each year. Despite the great progress in therapies available for patients with CVD, some limitations, including drug complications, still exist. Hence, the endocannabinoid system (ECS) was proposed as a new avenue for CVDs treatment. T...
Main Authors: | Sylwia Dziemitko, Ewa Harasim-Symbor, Adrian Chabowski |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-01-01
|
Series: | Therapeutic Advances in Chronic Disease |
Online Access: | https://doi.org/10.1177/20406223221143239 |
Similar Items
-
Cannabidiol improves muscular lipid profile by affecting the expression of fatty acid transporters and inhibiting de novo lipogenesis
by: Patrycja Bielawiec, et al.
Published: (2023-03-01) -
How Does CBG Administration Affect Sphingolipid Deposition in the Liver of Insulin-Resistant Rats?
by: Wiktor Bzdęga, et al.
Published: (2023-10-01) -
Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD
by: Klaudia Sztolsztener, et al.
Published: (2021-11-01) -
Chronic Cannabidiol Administration Attenuates Skeletal Muscle De Novo Ceramide Synthesis Pathway and Related Metabolic Effects in a Rat Model of High-Fat Diet-Induced Obesity
by: Patrycja Bielawiec, et al.
Published: (2020-08-01) -
Arachidonic Acid as an Early Indicator of Inflammation during Non-Alcoholic Fatty Liver Disease Development
by: Klaudia Sztolsztener, et al.
Published: (2020-07-01)